Hematology Analyzers Market Report 2026

The hematology analyzers market size has grown strongly in recent years. It will grow from $4.05 billion in 2025 to $4.34 billion in 2026 at a compound annual growth rate (CAGR) of 7.2%. The growth in the historic period can be attributed to expansion of clinical laboratory testing volumes, rising prevalence of blood-related disorders, increasing hospital diagnostic capabilities, adoption of automated lab instruments, improved access to routine blood testing.

The hematology analyzers market size is expected to see strong growth in the next few years. It will grow to $5.66 billion in 2030 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to rising demand for rapid diagnostics, increasing decentralization of laboratory testing, expansion of oncology and hematology diagnostics, growing adoption of digital pathology integration, increased focus on workflow automation. Major trends in the forecast period include increasing deployment of fully automated analyzers, rising integration of AI-assisted cell analysis, growing demand for point-of-care hematology testing, expansion of high-throughput laboratory systems, enhanced focus on diagnostic accuracy and speed.

The increasing incidence of blood disorders is anticipated to drive the growth of the hematology analyzers market in the coming years. Blood disorders are conditions that affect blood components such as red blood cells, white blood cells, platelets, or plasma. The rising incidence of blood disorders is largely attributed to the growing prevalence of chronic diseases, which directly influence blood health and require continuous monitoring. Hematology analyzers support the diagnosis of blood disorders by delivering precise and rapid analysis of blood components, allowing for timely detection and treatment. They enhance clinical decision-making, thereby improving patient care and outcomes. For example, in March 2024, according to the National Institute for Health and Care Excellence, a UK-based non-departmental public body, during 2022/2023, 2,069 individuals in the UK were diagnosed with haemophilia B, including 374 with severe disease and 351 with moderate disease. Therefore, the rising incidence of blood disorders is driving the growth of the hematology analyzers market.

Major companies operating in the hematology analyzers market are emphasizing the development of technologically advanced products, such as automated hematology systems, to enhance diagnostic accuracy, improve workflow efficiency, and deliver faster test results with minimal manual involvement. Automated hematology systems are advanced diagnostic instruments used in clinical laboratories to conduct a wide range of hematological tests with limited manual intervention. For instance, in January 2024, Horiba Medical, a Japan-based medical diagnostics company, introduced the HELO 2 high-throughput automated hematology platform, which is Conformité Européenne In Vitro Diagnostic Regulation (CE-IVDR) approved, with approval from the United States Food and Drug Administration (FDA) pending. HELO 2 provides a flexible, scalable, and efficient modular solution tailored to the requirements of mid- to large-scale laboratories. It incorporates advanced technologies from the Yumizen H2500 and H1500 analyzers, ensuring high-quality performance through 360-degree sample mixing, optimized turnaround time, efficient space utilization, and improved reagent storage. The platform also supports ISO-15189 accreditation assistance by addressing pre-analytical, analytical, and post-analytical needs.

In June 2023, Mars Incorporated, a US-based food company, acquired Heska Corporation for $1.3 billion. Through this acquisition, Mars aims to strengthen its footprint in the animal health diagnostics market, particularly in veterinary diagnostics, and further expand its portfolio of diagnostic solutions for veterinary professionals. Heska Corporation is a US-based veterinary diagnostics company specializing in diagnostic products, including hematology analyzers.

Major companies operating in the hematology analyzers market are F. Hoffmann-La Roche AG, Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG, Shenzhen Mindray Bio-Medical Electronics Co. Ltd., Sysmex Corporation, Horiba Medical Ltd., Nihon Kohden Corporation, Trivitron Healthcare Pvt. Ltd., Transasia Bio-Medicals Ltd., Erba Mannheim GmbH, Boule Diagnostics AB, Diatron MI PLC, Rayto Life and Analytical Sciences Co. Ltd., Perlong Medical, PZ Cormay S.A., Bio-Rad Laboratories Inc., BioSystems, EKF Diagnostics, Ortho Clinical Diagnostics, URIT Medical Electronic Group, Agappe Diagnostics.

North America was the largest region in the hematology analyzers market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hematology analyzers market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hematology analyzers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the hematology analyzers market by increasing costs of imported optical components, sensors, electronic modules, reagents, and precision instruments used in automated blood analysis systems. Hospitals and diagnostic laboratories in North America and Europe are most affected due to reliance on imported high-precision equipment, while Asia-Pacific faces cost pressure on analyzer manufacturing exports. These tariffs elevate procurement and maintenance costs for laboratories. However, they also support localized instrument assembly, regional consumable production, and long-term investment in domestic diagnostic manufacturing capabilities.

The hematology analyzers market research report is one of a series of new reports that provides hematology analyzers market statistics, including hematology analyzers industry global market size, regional shares, competitors with a hematology analyzers market share, detailed hematology analyzers market segments, market trends and opportunities, and any further data you may need to thrive in the hematology analyzers industry. This hematology analyzers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Hematology analyzers are automated laboratory instruments designed to count and analyze blood cells, including red blood cells, white blood cells, and platelets. They are used to diagnose and monitor conditions such as anemia, infections, clotting disorders, and blood cancers. The primary objective of these analyzers is to deliver accurate, rapid, and comprehensive blood test results to support clinical decision-making.

The primary forms of hematology analyzers include fully automated hematology analyzers and semi-automated hematology analyzers. Fully automated hematology analyzers are advanced laboratory systems developed to perform comprehensive blood analysis with minimal human involvement, automating processes such as sample preparation, cell counting, and result interpretation. Key components include instruments, reagents, and consumables, which are available in two main modalities: standalone and point-of-care. These devices employ advanced technologies such as flow cytometry, electrical impedance, and optical techniques, and are used by end users including hospitals, clinical laboratories, research institutions, and others.

The hematology analyzers market consists of sales of electrolyte analyzers, microplate readers, and diagnostic blood testing kits. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.